Global Clinical Oncology Next Generation Sequencing (NGS) Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Clinical Oncology Next Generation Sequencing (NGS) market size was valued at USD 725.1 million in 2023 and is forecast to a readjusted size of USD 1422.5 million by 2030 with a CAGR of 10.1% during review period.
NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
The Global Info Research report includes an overview of the development of the Clinical Oncology Next Generation Sequencing (NGS) industry chain, the market status of Academic & Clinical Research (NGS Pre-Sequencing, Sequencing), Hospitals & Clinics (NGS Pre-Sequencing, Sequencing), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Clinical Oncology Next Generation Sequencing (NGS).
Regionally, the report analyzes the Clinical Oncology Next Generation Sequencing (NGS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Clinical Oncology Next Generation Sequencing (NGS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Clinical Oncology Next Generation Sequencing (NGS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Clinical Oncology Next Generation Sequencing (NGS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., NGS Pre-Sequencing, Sequencing).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Clinical Oncology Next Generation Sequencing (NGS) market.
Regional Analysis: The report involves examining the Clinical Oncology Next Generation Sequencing (NGS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Clinical Oncology Next Generation Sequencing (NGS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Clinical Oncology Next Generation Sequencing (NGS):
Company Analysis: Report covers individual Clinical Oncology Next Generation Sequencing (NGS) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Clinical Oncology Next Generation Sequencing (NGS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Academic & Clinical Research, Hospitals & Clinics).
Technology Analysis: Report covers specific technologies relevant to Clinical Oncology Next Generation Sequencing (NGS). It assesses the current state, advancements, and potential future developments in Clinical Oncology Next Generation Sequencing (NGS) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Clinical Oncology Next Generation Sequencing (NGS) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Clinical Oncology Next Generation Sequencing (NGS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Clinical Oncology Next Generation Sequencing (NGS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Clinical Oncology Next Generation Sequencing (NGS), with revenue, gross margin and global market share of Clinical Oncology Next Generation Sequencing (NGS) from 2019 to 2024.
Chapter 3, the Clinical Oncology Next Generation Sequencing (NGS) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Clinical Oncology Next Generation Sequencing (NGS) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Clinical Oncology Next Generation Sequencing (NGS).
Chapter 13, to describe Clinical Oncology Next Generation Sequencing (NGS) research findings and conclusion.
NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
The Global Info Research report includes an overview of the development of the Clinical Oncology Next Generation Sequencing (NGS) industry chain, the market status of Academic & Clinical Research (NGS Pre-Sequencing, Sequencing), Hospitals & Clinics (NGS Pre-Sequencing, Sequencing), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Clinical Oncology Next Generation Sequencing (NGS).
Regionally, the report analyzes the Clinical Oncology Next Generation Sequencing (NGS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Clinical Oncology Next Generation Sequencing (NGS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Clinical Oncology Next Generation Sequencing (NGS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Clinical Oncology Next Generation Sequencing (NGS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., NGS Pre-Sequencing, Sequencing).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Clinical Oncology Next Generation Sequencing (NGS) market.
Regional Analysis: The report involves examining the Clinical Oncology Next Generation Sequencing (NGS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Clinical Oncology Next Generation Sequencing (NGS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Clinical Oncology Next Generation Sequencing (NGS):
Company Analysis: Report covers individual Clinical Oncology Next Generation Sequencing (NGS) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Clinical Oncology Next Generation Sequencing (NGS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Academic & Clinical Research, Hospitals & Clinics).
Technology Analysis: Report covers specific technologies relevant to Clinical Oncology Next Generation Sequencing (NGS). It assesses the current state, advancements, and potential future developments in Clinical Oncology Next Generation Sequencing (NGS) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Clinical Oncology Next Generation Sequencing (NGS) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Clinical Oncology Next Generation Sequencing (NGS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- NGS Pre-Sequencing
- Sequencing
- NGS Data Analysis
- Primary, Secondary & Tertiary Data Analysis
- Academic & Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Illumina
- Roche
- Agilent Technologies
- Knome
- Genomatix Software
- GATC Biotech
- Oxford Nanopore Technologies
- Macrogen
- Life Technologies
- DNASTAR
- Exosome Diagnostics
- Biomatters
- CLC Bio
- BGI
- Qiagen
- Perkin Elmer
- Pacific Bioscience
- Partek
- GnuBIO
- Foundation Medicine
- Paradigm
- Caris Life Sciences
- Myriad Genetics
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Clinical Oncology Next Generation Sequencing (NGS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Clinical Oncology Next Generation Sequencing (NGS), with revenue, gross margin and global market share of Clinical Oncology Next Generation Sequencing (NGS) from 2019 to 2024.
Chapter 3, the Clinical Oncology Next Generation Sequencing (NGS) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Clinical Oncology Next Generation Sequencing (NGS) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Clinical Oncology Next Generation Sequencing (NGS).
Chapter 13, to describe Clinical Oncology Next Generation Sequencing (NGS) research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Clinical Oncology Next Generation Sequencing (NGS)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Clinical Oncology Next Generation Sequencing (NGS) by Type
1.3.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type in 2023
1.3.3 NGS Pre-Sequencing
1.3.4 Sequencing
1.3.5 NGS Data Analysis
1.3.6 Primary, Secondary & Tertiary Data Analysis
1.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application
1.4.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Academic & Clinical Research
1.4.3 Hospitals & Clinics
1.4.4 Pharma & Biotech Entities
1.5 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast
1.6 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast by Region
1.6.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region, (2019-2030)
1.6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.6 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Illumina
2.1.1 Illumina Details
2.1.2 Illumina Major Business
2.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.1.4 Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Illumina Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.2.4 Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Roche Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.3.4 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Knome
2.4.1 Knome Details
2.4.2 Knome Major Business
2.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.4.4 Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Knome Recent Developments and Future Plans
2.5 Genomatix Software
2.5.1 Genomatix Software Details
2.5.2 Genomatix Software Major Business
2.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.5.4 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Genomatix Software Recent Developments and Future Plans
2.6 GATC Biotech
2.6.1 GATC Biotech Details
2.6.2 GATC Biotech Major Business
2.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.6.4 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 GATC Biotech Recent Developments and Future Plans
2.7 Oxford Nanopore Technologies
2.7.1 Oxford Nanopore Technologies Details
2.7.2 Oxford Nanopore Technologies Major Business
2.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.7.4 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Oxford Nanopore Technologies Recent Developments and Future Plans
2.8 Macrogen
2.8.1 Macrogen Details
2.8.2 Macrogen Major Business
2.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.8.4 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Macrogen Recent Developments and Future Plans
2.9 Life Technologies
2.9.1 Life Technologies Details
2.9.2 Life Technologies Major Business
2.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.9.4 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Life Technologies Recent Developments and Future Plans
2.10 DNASTAR
2.10.1 DNASTAR Details
2.10.2 DNASTAR Major Business
2.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.10.4 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 DNASTAR Recent Developments and Future Plans
2.11 Exosome Diagnostics
2.11.1 Exosome Diagnostics Details
2.11.2 Exosome Diagnostics Major Business
2.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.11.4 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Exosome Diagnostics Recent Developments and Future Plans
2.12 Biomatters
2.12.1 Biomatters Details
2.12.2 Biomatters Major Business
2.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.12.4 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Biomatters Recent Developments and Future Plans
2.13 CLC Bio
2.13.1 CLC Bio Details
2.13.2 CLC Bio Major Business
2.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.13.4 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 CLC Bio Recent Developments and Future Plans
2.14 BGI
2.14.1 BGI Details
2.14.2 BGI Major Business
2.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.14.4 BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 BGI Recent Developments and Future Plans
2.15 Qiagen
2.15.1 Qiagen Details
2.15.2 Qiagen Major Business
2.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.15.4 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Qiagen Recent Developments and Future Plans
2.16 Perkin Elmer
2.16.1 Perkin Elmer Details
2.16.2 Perkin Elmer Major Business
2.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.16.4 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Perkin Elmer Recent Developments and Future Plans
2.17 Pacific Bioscience
2.17.1 Pacific Bioscience Details
2.17.2 Pacific Bioscience Major Business
2.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.17.4 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 Pacific Bioscience Recent Developments and Future Plans
2.18 Partek
2.18.1 Partek Details
2.18.2 Partek Major Business
2.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.18.4 Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.18.5 Partek Recent Developments and Future Plans
2.19 GnuBIO
2.19.1 GnuBIO Details
2.19.2 GnuBIO Major Business
2.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.19.4 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.19.5 GnuBIO Recent Developments and Future Plans
2.20 Foundation Medicine
2.20.1 Foundation Medicine Details
2.20.2 Foundation Medicine Major Business
2.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.20.4 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.20.5 Foundation Medicine Recent Developments and Future Plans
2.21 Paradigm
2.21.1 Paradigm Details
2.21.2 Paradigm Major Business
2.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.21.4 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.21.5 Paradigm Recent Developments and Future Plans
2.22 Caris Life Sciences
2.22.1 Caris Life Sciences Details
2.22.2 Caris Life Sciences Major Business
2.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.22.4 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.22.5 Caris Life Sciences Recent Developments and Future Plans
2.23 Myriad Genetics
2.23.1 Myriad Genetics Details
2.23.2 Myriad Genetics Major Business
2.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.23.4 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.23.5 Myriad Genetics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Clinical Oncology Next Generation Sequencing (NGS) by Company Revenue
3.2.2 Top 3 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share in 2023
3.2.3 Top 6 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share in 2023
3.3 Clinical Oncology Next Generation Sequencing (NGS) Market: Overall Company Footprint Analysis
3.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market: Region Footprint
3.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Type Footprint
3.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2024)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
6.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
6.3.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
6.3.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
6.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
7.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
7.3.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.3 France Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.5 Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.6 Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region
8.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2019-2030)
8.3.2 China Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.5 India Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.7 Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
9.2 South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
9.3 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
9.3.1 South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
9.3.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
9.3.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
10.3.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
10.3.2 Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
10.3.4 UAE Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
11.2 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
11.3 Clinical Oncology Next Generation Sequencing (NGS) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Chain
12.2 Clinical Oncology Next Generation Sequencing (NGS) Upstream Analysis
12.3 Clinical Oncology Next Generation Sequencing (NGS) Midstream Analysis
12.4 Clinical Oncology Next Generation Sequencing (NGS) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Clinical Oncology Next Generation Sequencing (NGS)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Clinical Oncology Next Generation Sequencing (NGS) by Type
1.3.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type in 2023
1.3.3 NGS Pre-Sequencing
1.3.4 Sequencing
1.3.5 NGS Data Analysis
1.3.6 Primary, Secondary & Tertiary Data Analysis
1.4 Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application
1.4.1 Overview: Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Academic & Clinical Research
1.4.3 Hospitals & Clinics
1.4.4 Pharma & Biotech Entities
1.5 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast
1.6 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast by Region
1.6.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region, (2019-2030)
1.6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.6 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Illumina
2.1.1 Illumina Details
2.1.2 Illumina Major Business
2.1.3 Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.1.4 Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Illumina Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.2.4 Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Roche Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.3.4 Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Knome
2.4.1 Knome Details
2.4.2 Knome Major Business
2.4.3 Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.4.4 Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Knome Recent Developments and Future Plans
2.5 Genomatix Software
2.5.1 Genomatix Software Details
2.5.2 Genomatix Software Major Business
2.5.3 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.5.4 Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Genomatix Software Recent Developments and Future Plans
2.6 GATC Biotech
2.6.1 GATC Biotech Details
2.6.2 GATC Biotech Major Business
2.6.3 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.6.4 GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 GATC Biotech Recent Developments and Future Plans
2.7 Oxford Nanopore Technologies
2.7.1 Oxford Nanopore Technologies Details
2.7.2 Oxford Nanopore Technologies Major Business
2.7.3 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.7.4 Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Oxford Nanopore Technologies Recent Developments and Future Plans
2.8 Macrogen
2.8.1 Macrogen Details
2.8.2 Macrogen Major Business
2.8.3 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.8.4 Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Macrogen Recent Developments and Future Plans
2.9 Life Technologies
2.9.1 Life Technologies Details
2.9.2 Life Technologies Major Business
2.9.3 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.9.4 Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Life Technologies Recent Developments and Future Plans
2.10 DNASTAR
2.10.1 DNASTAR Details
2.10.2 DNASTAR Major Business
2.10.3 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.10.4 DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 DNASTAR Recent Developments and Future Plans
2.11 Exosome Diagnostics
2.11.1 Exosome Diagnostics Details
2.11.2 Exosome Diagnostics Major Business
2.11.3 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.11.4 Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Exosome Diagnostics Recent Developments and Future Plans
2.12 Biomatters
2.12.1 Biomatters Details
2.12.2 Biomatters Major Business
2.12.3 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.12.4 Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Biomatters Recent Developments and Future Plans
2.13 CLC Bio
2.13.1 CLC Bio Details
2.13.2 CLC Bio Major Business
2.13.3 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.13.4 CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 CLC Bio Recent Developments and Future Plans
2.14 BGI
2.14.1 BGI Details
2.14.2 BGI Major Business
2.14.3 BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.14.4 BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 BGI Recent Developments and Future Plans
2.15 Qiagen
2.15.1 Qiagen Details
2.15.2 Qiagen Major Business
2.15.3 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.15.4 Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Qiagen Recent Developments and Future Plans
2.16 Perkin Elmer
2.16.1 Perkin Elmer Details
2.16.2 Perkin Elmer Major Business
2.16.3 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.16.4 Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Perkin Elmer Recent Developments and Future Plans
2.17 Pacific Bioscience
2.17.1 Pacific Bioscience Details
2.17.2 Pacific Bioscience Major Business
2.17.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.17.4 Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 Pacific Bioscience Recent Developments and Future Plans
2.18 Partek
2.18.1 Partek Details
2.18.2 Partek Major Business
2.18.3 Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.18.4 Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.18.5 Partek Recent Developments and Future Plans
2.19 GnuBIO
2.19.1 GnuBIO Details
2.19.2 GnuBIO Major Business
2.19.3 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.19.4 GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.19.5 GnuBIO Recent Developments and Future Plans
2.20 Foundation Medicine
2.20.1 Foundation Medicine Details
2.20.2 Foundation Medicine Major Business
2.20.3 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.20.4 Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.20.5 Foundation Medicine Recent Developments and Future Plans
2.21 Paradigm
2.21.1 Paradigm Details
2.21.2 Paradigm Major Business
2.21.3 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.21.4 Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.21.5 Paradigm Recent Developments and Future Plans
2.22 Caris Life Sciences
2.22.1 Caris Life Sciences Details
2.22.2 Caris Life Sciences Major Business
2.22.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.22.4 Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.22.5 Caris Life Sciences Recent Developments and Future Plans
2.23 Myriad Genetics
2.23.1 Myriad Genetics Details
2.23.2 Myriad Genetics Major Business
2.23.3 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
2.23.4 Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue, Gross Margin and Market Share (2019-2024)
2.23.5 Myriad Genetics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Clinical Oncology Next Generation Sequencing (NGS) by Company Revenue
3.2.2 Top 3 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share in 2023
3.2.3 Top 6 Clinical Oncology Next Generation Sequencing (NGS) Players Market Share in 2023
3.3 Clinical Oncology Next Generation Sequencing (NGS) Market: Overall Company Footprint Analysis
3.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market: Region Footprint
3.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Type Footprint
3.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2024)
5.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
6.2 North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
6.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
6.3.1 North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
6.3.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
6.3.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
6.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
7.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
7.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
7.3.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
7.3.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.3 France Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.5 Russia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
7.3.6 Italy Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Size by Region
8.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2019-2030)
8.3.2 China Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.5 India Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
8.3.7 Australia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
9.2 South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
9.3 South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
9.3.1 South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
9.3.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
9.3.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Market Size by Country
10.3.1 Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2030)
10.3.2 Turkey Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
10.3.4 UAE Clinical Oncology Next Generation Sequencing (NGS) Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
11.2 Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
11.3 Clinical Oncology Next Generation Sequencing (NGS) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Clinical Oncology Next Generation Sequencing (NGS) Industry Chain
12.2 Clinical Oncology Next Generation Sequencing (NGS) Upstream Analysis
12.3 Clinical Oncology Next Generation Sequencing (NGS) Midstream Analysis
12.4 Clinical Oncology Next Generation Sequencing (NGS) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Illumina Company Information, Head Office, and Major Competitors
Table 6. Illumina Major Business
Table 7. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 8. Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Illumina Recent Developments and Future Plans
Table 10. Roche Company Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 13. Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Roche Recent Developments and Future Plans
Table 15. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 16. Agilent Technologies Major Business
Table 17. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 18. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Agilent Technologies Recent Developments and Future Plans
Table 20. Knome Company Information, Head Office, and Major Competitors
Table 21. Knome Major Business
Table 22. Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 23. Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Knome Recent Developments and Future Plans
Table 25. Genomatix Software Company Information, Head Office, and Major Competitors
Table 26. Genomatix Software Major Business
Table 27. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 28. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Genomatix Software Recent Developments and Future Plans
Table 30. GATC Biotech Company Information, Head Office, and Major Competitors
Table 31. GATC Biotech Major Business
Table 32. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 33. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. GATC Biotech Recent Developments and Future Plans
Table 35. Oxford Nanopore Technologies Company Information, Head Office, and Major Competitors
Table 36. Oxford Nanopore Technologies Major Business
Table 37. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 38. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Oxford Nanopore Technologies Recent Developments and Future Plans
Table 40. Macrogen Company Information, Head Office, and Major Competitors
Table 41. Macrogen Major Business
Table 42. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 43. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Macrogen Recent Developments and Future Plans
Table 45. Life Technologies Company Information, Head Office, and Major Competitors
Table 46. Life Technologies Major Business
Table 47. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 48. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Life Technologies Recent Developments and Future Plans
Table 50. DNASTAR Company Information, Head Office, and Major Competitors
Table 51. DNASTAR Major Business
Table 52. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 53. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. DNASTAR Recent Developments and Future Plans
Table 55. Exosome Diagnostics Company Information, Head Office, and Major Competitors
Table 56. Exosome Diagnostics Major Business
Table 57. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 58. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Exosome Diagnostics Recent Developments and Future Plans
Table 60. Biomatters Company Information, Head Office, and Major Competitors
Table 61. Biomatters Major Business
Table 62. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 63. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Biomatters Recent Developments and Future Plans
Table 65. CLC Bio Company Information, Head Office, and Major Competitors
Table 66. CLC Bio Major Business
Table 67. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 68. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. CLC Bio Recent Developments and Future Plans
Table 70. BGI Company Information, Head Office, and Major Competitors
Table 71. BGI Major Business
Table 72. BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 73. BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 74. BGI Recent Developments and Future Plans
Table 75. Qiagen Company Information, Head Office, and Major Competitors
Table 76. Qiagen Major Business
Table 77. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 78. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 79. Qiagen Recent Developments and Future Plans
Table 80. Perkin Elmer Company Information, Head Office, and Major Competitors
Table 81. Perkin Elmer Major Business
Table 82. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 83. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 84. Perkin Elmer Recent Developments and Future Plans
Table 85. Pacific Bioscience Company Information, Head Office, and Major Competitors
Table 86. Pacific Bioscience Major Business
Table 87. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 88. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Pacific Bioscience Recent Developments and Future Plans
Table 90. Partek Company Information, Head Office, and Major Competitors
Table 91. Partek Major Business
Table 92. Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 93. Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 94. Partek Recent Developments and Future Plans
Table 95. GnuBIO Company Information, Head Office, and Major Competitors
Table 96. GnuBIO Major Business
Table 97. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 98. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 99. GnuBIO Recent Developments and Future Plans
Table 100. Foundation Medicine Company Information, Head Office, and Major Competitors
Table 101. Foundation Medicine Major Business
Table 102. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 103. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 104. Foundation Medicine Recent Developments and Future Plans
Table 105. Paradigm Company Information, Head Office, and Major Competitors
Table 106. Paradigm Major Business
Table 107. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 108. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 109. Paradigm Recent Developments and Future Plans
Table 110. Caris Life Sciences Company Information, Head Office, and Major Competitors
Table 111. Caris Life Sciences Major Business
Table 112. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 113. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 114. Caris Life Sciences Recent Developments and Future Plans
Table 115. Myriad Genetics Company Information, Head Office, and Major Competitors
Table 116. Myriad Genetics Major Business
Table 117. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 118. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 119. Myriad Genetics Recent Developments and Future Plans
Table 120. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Players (2019-2024)
Table 121. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players (2019-2024)
Table 122. Breakdown of Clinical Oncology Next Generation Sequencing (NGS) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 123. Market Position of Players in Clinical Oncology Next Generation Sequencing (NGS), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 124. Head Office of Key Clinical Oncology Next Generation Sequencing (NGS) Players
Table 125. Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Type Footprint
Table 126. Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Application Footprint
Table 127. Clinical Oncology Next Generation Sequencing (NGS) New Market Entrants and Barriers to Market Entry
Table 128. Clinical Oncology Next Generation Sequencing (NGS) Mergers, Acquisition, Agreements, and Collaborations
Table 129. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (USD Million) by Type (2019-2024)
Table 130. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Share by Type (2019-2024)
Table 131. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Forecast by Type (2025-2030)
Table 132. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024)
Table 133. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Forecast by Application (2025-2030)
Table 134. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 135. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 136. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 137. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 138. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 139. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 140. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 141. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 142. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 143. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 144. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 145. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 146. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 147. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 148. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 149. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 150. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2019-2024) & (USD Million)
Table 151. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2025-2030) & (USD Million)
Table 152. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 153. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 154. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 155. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 156. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 157. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 158. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 159. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 160. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 161. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 162. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 163. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 164. Clinical Oncology Next Generation Sequencing (NGS) Raw Material
Table 165. Key Suppliers of Clinical Oncology Next Generation Sequencing (NGS) Raw Materials
Table 1. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Illumina Company Information, Head Office, and Major Competitors
Table 6. Illumina Major Business
Table 7. Illumina Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 8. Illumina Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Illumina Recent Developments and Future Plans
Table 10. Roche Company Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 13. Roche Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Roche Recent Developments and Future Plans
Table 15. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 16. Agilent Technologies Major Business
Table 17. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 18. Agilent Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Agilent Technologies Recent Developments and Future Plans
Table 20. Knome Company Information, Head Office, and Major Competitors
Table 21. Knome Major Business
Table 22. Knome Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 23. Knome Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Knome Recent Developments and Future Plans
Table 25. Genomatix Software Company Information, Head Office, and Major Competitors
Table 26. Genomatix Software Major Business
Table 27. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 28. Genomatix Software Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Genomatix Software Recent Developments and Future Plans
Table 30. GATC Biotech Company Information, Head Office, and Major Competitors
Table 31. GATC Biotech Major Business
Table 32. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 33. GATC Biotech Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. GATC Biotech Recent Developments and Future Plans
Table 35. Oxford Nanopore Technologies Company Information, Head Office, and Major Competitors
Table 36. Oxford Nanopore Technologies Major Business
Table 37. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 38. Oxford Nanopore Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Oxford Nanopore Technologies Recent Developments and Future Plans
Table 40. Macrogen Company Information, Head Office, and Major Competitors
Table 41. Macrogen Major Business
Table 42. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 43. Macrogen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Macrogen Recent Developments and Future Plans
Table 45. Life Technologies Company Information, Head Office, and Major Competitors
Table 46. Life Technologies Major Business
Table 47. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 48. Life Technologies Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Life Technologies Recent Developments and Future Plans
Table 50. DNASTAR Company Information, Head Office, and Major Competitors
Table 51. DNASTAR Major Business
Table 52. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 53. DNASTAR Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. DNASTAR Recent Developments and Future Plans
Table 55. Exosome Diagnostics Company Information, Head Office, and Major Competitors
Table 56. Exosome Diagnostics Major Business
Table 57. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 58. Exosome Diagnostics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Exosome Diagnostics Recent Developments and Future Plans
Table 60. Biomatters Company Information, Head Office, and Major Competitors
Table 61. Biomatters Major Business
Table 62. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 63. Biomatters Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 64. Biomatters Recent Developments and Future Plans
Table 65. CLC Bio Company Information, Head Office, and Major Competitors
Table 66. CLC Bio Major Business
Table 67. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 68. CLC Bio Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 69. CLC Bio Recent Developments and Future Plans
Table 70. BGI Company Information, Head Office, and Major Competitors
Table 71. BGI Major Business
Table 72. BGI Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 73. BGI Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 74. BGI Recent Developments and Future Plans
Table 75. Qiagen Company Information, Head Office, and Major Competitors
Table 76. Qiagen Major Business
Table 77. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 78. Qiagen Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 79. Qiagen Recent Developments and Future Plans
Table 80. Perkin Elmer Company Information, Head Office, and Major Competitors
Table 81. Perkin Elmer Major Business
Table 82. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 83. Perkin Elmer Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 84. Perkin Elmer Recent Developments and Future Plans
Table 85. Pacific Bioscience Company Information, Head Office, and Major Competitors
Table 86. Pacific Bioscience Major Business
Table 87. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 88. Pacific Bioscience Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 89. Pacific Bioscience Recent Developments and Future Plans
Table 90. Partek Company Information, Head Office, and Major Competitors
Table 91. Partek Major Business
Table 92. Partek Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 93. Partek Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 94. Partek Recent Developments and Future Plans
Table 95. GnuBIO Company Information, Head Office, and Major Competitors
Table 96. GnuBIO Major Business
Table 97. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 98. GnuBIO Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 99. GnuBIO Recent Developments and Future Plans
Table 100. Foundation Medicine Company Information, Head Office, and Major Competitors
Table 101. Foundation Medicine Major Business
Table 102. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 103. Foundation Medicine Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 104. Foundation Medicine Recent Developments and Future Plans
Table 105. Paradigm Company Information, Head Office, and Major Competitors
Table 106. Paradigm Major Business
Table 107. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 108. Paradigm Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 109. Paradigm Recent Developments and Future Plans
Table 110. Caris Life Sciences Company Information, Head Office, and Major Competitors
Table 111. Caris Life Sciences Major Business
Table 112. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 113. Caris Life Sciences Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 114. Caris Life Sciences Recent Developments and Future Plans
Table 115. Myriad Genetics Company Information, Head Office, and Major Competitors
Table 116. Myriad Genetics Major Business
Table 117. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Product and Solutions
Table 118. Myriad Genetics Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 119. Myriad Genetics Recent Developments and Future Plans
Table 120. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue (USD Million) by Players (2019-2024)
Table 121. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players (2019-2024)
Table 122. Breakdown of Clinical Oncology Next Generation Sequencing (NGS) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 123. Market Position of Players in Clinical Oncology Next Generation Sequencing (NGS), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 124. Head Office of Key Clinical Oncology Next Generation Sequencing (NGS) Players
Table 125. Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Type Footprint
Table 126. Clinical Oncology Next Generation Sequencing (NGS) Market: Company Product Application Footprint
Table 127. Clinical Oncology Next Generation Sequencing (NGS) New Market Entrants and Barriers to Market Entry
Table 128. Clinical Oncology Next Generation Sequencing (NGS) Mergers, Acquisition, Agreements, and Collaborations
Table 129. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (USD Million) by Type (2019-2024)
Table 130. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Share by Type (2019-2024)
Table 131. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Forecast by Type (2025-2030)
Table 132. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024)
Table 133. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Forecast by Application (2025-2030)
Table 134. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 135. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 136. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 137. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 138. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 139. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 140. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 141. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 142. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 143. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 144. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 145. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 146. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 147. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 148. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 149. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 150. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2019-2024) & (USD Million)
Table 151. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Region (2025-2030) & (USD Million)
Table 152. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 153. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 154. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 155. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 156. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 157. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 158. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2019-2024) & (USD Million)
Table 159. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type (2025-2030) & (USD Million)
Table 160. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2019-2024) & (USD Million)
Table 161. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Application (2025-2030) & (USD Million)
Table 162. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2019-2024) & (USD Million)
Table 163. Middle East & Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Country (2025-2030) & (USD Million)
Table 164. Clinical Oncology Next Generation Sequencing (NGS) Raw Material
Table 165. Key Suppliers of Clinical Oncology Next Generation Sequencing (NGS) Raw Materials
LIST OF FIGURES
Figure 1. Clinical Oncology Next Generation Sequencing (NGS) Picture
Figure 2. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type in 2023
Figure 4. NGS Pre-Sequencing
Figure 5. Sequencing
Figure 6. NGS Data Analysis
Figure 7. Primary, Secondary & Tertiary Data Analysis
Figure 8. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 9. Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application in 2023
Figure 10. Academic & Clinical Research Picture
Figure 11. Hospitals & Clinics Picture
Figure 12. Pharma & Biotech Entities Picture
Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Region (2019-2030)
Figure 17. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Region in 2023
Figure 18. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 21. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 23. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players in 2023
Figure 24. Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players Clinical Oncology Next Generation Sequencing (NGS) Market Share in 2023
Figure 26. Global Top 6 Players Clinical Oncology Next Generation Sequencing (NGS) Market Share in 2023
Figure 27. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Share by Type (2019-2024)
Figure 28. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Type (2025-2030)
Figure 29. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Share by Application (2019-2024)
Figure 30. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Application (2025-2030)
Figure 31. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 32. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 33. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 34. United States Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 41. France Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Region (2019-2030)
Figure 48. China Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 51. India Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 54. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 55. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 56. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 65. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
Figure 66. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
Figure 67. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Clinical Oncology Next Generation Sequencing (NGS) in 2023
Figure 70. Manufacturing Process Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Figure 71. Clinical Oncology Next Generation Sequencing (NGS) Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Clinical Oncology Next Generation Sequencing (NGS) Picture
Figure 2. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type in 2023
Figure 4. NGS Pre-Sequencing
Figure 5. Sequencing
Figure 6. NGS Data Analysis
Figure 7. Primary, Secondary & Tertiary Data Analysis
Figure 8. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 9. Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application in 2023
Figure 10. Academic & Clinical Research Picture
Figure 11. Hospitals & Clinics Picture
Figure 12. Pharma & Biotech Entities Picture
Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Region (2019-2030)
Figure 17. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Region in 2023
Figure 18. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 21. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 23. Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Share by Players in 2023
Figure 24. Clinical Oncology Next Generation Sequencing (NGS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players Clinical Oncology Next Generation Sequencing (NGS) Market Share in 2023
Figure 26. Global Top 6 Players Clinical Oncology Next Generation Sequencing (NGS) Market Share in 2023
Figure 27. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Share by Type (2019-2024)
Figure 28. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Type (2025-2030)
Figure 29. Global Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Share by Application (2019-2024)
Figure 30. Global Clinical Oncology Next Generation Sequencing (NGS) Market Share Forecast by Application (2025-2030)
Figure 31. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 32. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 33. North America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 34. United States Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 41. France Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Region (2019-2030)
Figure 48. China Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 51. India Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 54. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 55. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 56. South America Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE Clinical Oncology Next Generation Sequencing (NGS) Consumption Value (2019-2030) & (USD Million)
Figure 65. Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
Figure 66. Clinical Oncology Next Generation Sequencing (NGS) Market Restraints
Figure 67. Clinical Oncology Next Generation Sequencing (NGS) Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Clinical Oncology Next Generation Sequencing (NGS) in 2023
Figure 70. Manufacturing Process Analysis of Clinical Oncology Next Generation Sequencing (NGS)
Figure 71. Clinical Oncology Next Generation Sequencing (NGS) Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
